A phenotype-genotype approach to predicting CYP450 and P-glycoprotein drug interactions with the mixed inhibitor/inducer tipranavir/ritonavir
about
Assessment of the pharmacokinetic interaction between eltrombopag and lopinavir-ritonavir in healthy adult subjects.Geneva cocktail for cytochrome p450 and P-glycoprotein activity assessment using dried blood spots.Binary and ternary combinations of anti-HIV protease inhibitors: effect on gene expression and functional activity of CYP3A4 and efflux transporters.Editorial neuroAIDS review.Influence of drug transport proteins on the pharmacokinetics and drug interactions of HIV protease inhibitors.Safety and pharmacokinetics of escalating daily doses of the antituberculosis drug rifapentine in healthy volunteers.Antiretroviral drug interactions: overview of interactions involving new and investigational agents and the role of therapeutic drug monitoring for management.Methadone, buprenorphine, and street drug interactions with antiretroviral medicationsThe effect of ABCB1 genetic variants on chemotherapy response in HIV and cancer treatment.Induction of cytochrome P450 enzymes: a view on human in vivo findings.Drug Interactions With Direct-Acting Antivirals for Hepatitis C: Implications for HIV and Transplant Patients.Interactions of the hepatitis C virus protease inhibitor faldaprevir with cytochrome P450 enzymes: in vitro and in vivo correlation.Safety and pharmacokinetics of the CIME combination of drugs and their metabolites after a single oral dosing in healthy volunteers.A randomised study of the effect of danoprevir/ritonavir or ritonavir on substrates of cytochrome P450 (CYP) 3A and 2C9 in chronic hepatitis C patients using a drug cocktail.Prediction of drug response and safety in clinical practice.Paritaprevir/ritonavir/ombitasvir+dasabuvir plus ribavirin therapy and inhibition of the anticoagulant effect of warfarin: a case report.Clarification of P-glycoprotein inhibition-related drug-drug interaction risks based on a literature search of the clinical information.Tipranavir/Ritonavir Induction of Buprenorphine Glucuronide Metabolism in HIV-Negative Subjects Chronically Receiving Buprenorphine/Naloxone
P2860
Q33400092-D17C717E-9F20-422B-A4B6-C89921D0D424Q34116690-38BF52C4-272B-449B-80AF-D1C5F1597272Q35531564-6B457311-479A-4212-A47E-3F495327D2DEQ35731648-D710881E-4F01-40C0-9909-F13452CD3520Q37113947-90AD619D-3BA6-429D-8EC6-F6094C3DBAEFQ37334396-93015256-5204-4727-B6B5-A54245B2E64BQ37378110-24093382-0235-4427-AC49-5B57DD32F826Q37763615-B9000595-AC79-45D3-B7E9-8BCC13290B8AQ37946959-CD839AF9-0F1D-41A5-81CE-558D0AEF3A16Q38057372-8160394B-F925-4C11-9732-182FCB736C9CQ38377264-2287CC29-A01E-4707-94B8-731E36A004CEQ41634295-2EB22178-2FDB-4686-BC08-5487690B0C57Q41737190-EB36BB78-9206-417D-95EC-AD6E0A3030B6Q42282507-D98065AF-08F5-4890-95A9-DB23C3F445A8Q42870458-57A10D3C-FEE3-4548-9B6E-5C95DD0B541CQ47999149-68175B93-73D3-4419-B5A0-1105CD1659C5Q50668713-1FB95DA4-BEE2-48CE-804C-C50C3D1B6E5DQ58143296-A7B042C5-595C-4221-B0F9-8011EB9333F0
P2860
A phenotype-genotype approach to predicting CYP450 and P-glycoprotein drug interactions with the mixed inhibitor/inducer tipranavir/ritonavir
description
2010 nî lūn-bûn
@nan
2010 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
A phenotype-genotype approach ...... r/inducer tipranavir/ritonavir
@ast
A phenotype-genotype approach ...... r/inducer tipranavir/ritonavir
@en
type
label
A phenotype-genotype approach ...... r/inducer tipranavir/ritonavir
@ast
A phenotype-genotype approach ...... r/inducer tipranavir/ritonavir
@en
prefLabel
A phenotype-genotype approach ...... r/inducer tipranavir/ritonavir
@ast
A phenotype-genotype approach ...... r/inducer tipranavir/ritonavir
@en
P2093
P2860
P356
P1476
A phenotype-genotype approach ...... r/inducer tipranavir/ritonavir
@en
P2093
A D M Kashuba
J B Dumond
K B Patterson
M A Castles
M J Wagner
M Vourvahis
P2860
P2888
P304
P356
10.1038/CLPT.2009.253
P407
P577
2010-02-10T00:00:00Z
P5875
P6179
1052976036